State of Alaska Department of Revenue Sells 6,280 Shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH)

State of Alaska Department of Revenue trimmed its stake in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 21.7% in the fourth quarter, according to the company in its most recent filing with the SEC. The firm owned 22,696 shares of the medical equipment provider’s stock after selling 6,280 shares during the quarter. State of Alaska Department of Revenue’s holdings in Zimmer Biomet were worth $2,397,000 as of its most recent SEC filing.

A number of other institutional investors have also recently modified their holdings of the stock. Geode Capital Management LLC lifted its position in shares of Zimmer Biomet by 2.6% during the 3rd quarter. Geode Capital Management LLC now owns 4,879,385 shares of the medical equipment provider’s stock worth $524,942,000 after buying an additional 125,852 shares during the last quarter. M&T Bank Corp lifted its position in shares of Zimmer Biomet by 48.4% during the 3rd quarter. M&T Bank Corp now owns 26,719 shares of the medical equipment provider’s stock worth $2,884,000 after buying an additional 8,709 shares during the last quarter. Peddock Capital Advisors LLC bought a new stake in shares of Zimmer Biomet during the 4th quarter worth $654,000. National Pension Service lifted its position in shares of Zimmer Biomet by 3.8% during the 3rd quarter. National Pension Service now owns 369,547 shares of the medical equipment provider’s stock worth $39,893,000 after buying an additional 13,612 shares during the last quarter. Finally, River Global Investors LLP lifted its position in shares of Zimmer Biomet by 31.3% during the 3rd quarter. River Global Investors LLP now owns 21,084 shares of the medical equipment provider’s stock worth $2,276,000 after buying an additional 5,030 shares during the last quarter. 88.89% of the stock is currently owned by institutional investors.

Zimmer Biomet Trading Down 0.5 %

Shares of Zimmer Biomet stock opened at $100.40 on Tuesday. The company has a debt-to-equity ratio of 0.43, a quick ratio of 0.70 and a current ratio of 1.91. Zimmer Biomet Holdings, Inc. has a 52 week low of $99.67 and a 52 week high of $133.90. The stock has a 50 day moving average price of $107.34 and a two-hundred day moving average price of $108.07. The stock has a market capitalization of $19.99 billion, a PE ratio of 22.56, a price-to-earnings-growth ratio of 1.83 and a beta of 1.02.

Zimmer Biomet (NYSE:ZBH) last announced its quarterly earnings data on Thursday, February 6th. The medical equipment provider reported $2.31 EPS for the quarter, beating analysts’ consensus estimates of $2.30 by $0.01. Zimmer Biomet had a return on equity of 12.99% and a net margin of 11.77%. During the same period in the previous year, the firm earned $2.20 earnings per share. As a group, equities analysts anticipate that Zimmer Biomet Holdings, Inc. will post 8.25 earnings per share for the current fiscal year.

Zimmer Biomet Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Friday, January 31st. Stockholders of record on Monday, December 30th were issued a $0.24 dividend. The ex-dividend date was Monday, December 30th. This represents a $0.96 dividend on an annualized basis and a dividend yield of 0.96%. Zimmer Biomet’s dividend payout ratio is presently 21.57%.

Analyst Upgrades and Downgrades

Several equities analysts have commented on the company. Truist Financial reiterated a “hold” rating and issued a $113.00 target price (down from $118.00) on shares of Zimmer Biomet in a research report on Monday. Oppenheimer dropped their target price on Zimmer Biomet from $145.00 to $135.00 and set an “outperform” rating for the company in a research report on Tuesday, October 15th. Stifel Nicolaus increased their target price on Zimmer Biomet from $130.00 to $138.00 and gave the company a “buy” rating in a research report on Thursday, January 23rd. JMP Securities reiterated a “market outperform” rating and issued a $140.00 target price on shares of Zimmer Biomet in a research report on Friday. Finally, Wells Fargo & Company increased their price target on Zimmer Biomet from $110.00 to $117.00 and gave the company an “equal weight” rating in a research note on Thursday, October 31st. Two research analysts have rated the stock with a sell rating, eleven have assigned a hold rating and ten have assigned a buy rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Hold” and an average price target of $124.15.

About Zimmer Biomet

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.